Autres langues Santhera Pharmaceuticals Holding AG

Actions

SANN

CH1276028821

Temps réel estimé Cboe Europe Autres places de cotation 12:29:43 26/04/2024			Varia. 5j.	Varia. 1 janv.
9,51 ^CHF	+0,11 %		+4,28 %	-3,16 %

25/04	Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024
25/04	Santhera dans les chiffres noirs en 2023	AW

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	25/04
Santhera dank Catalyst-Deal mit gutem Finanzpuffer - ab 2026 Break-Even geplant	25/04
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May	25/04
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	25/04
Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	17/04
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	27/03
Santhera kommt mit möglicher Zulassung von Vamorolon in China entscheidend voran	27/03
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA	27/03
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	27/03
Santhera-Partner Catalyst Pharmaceuticals lanciert Agamree in den USA	14/03
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States	14/03
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	21/02
Aktien Schweiz auf Erholungskurs	14/02
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment	14/02
Santhera veröffentlicht Daten über Vamorolon in Fachjournal 'Neurology'	14/02
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology	14/02
Santhera lanciert DMD-Mittel Agamree zuerst in Deutschland - weltweite Premiere	15/01
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	15/01
Santhera Pharmaceuticals Holding AG Launches AGAMREE in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	15/01
Swiss Equities Get a Boost from UK’s Upside GDP Surprise	12/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Santhera Pharmaceuticals Holding AG

Actions

SANN

CH1276028821

Autres langues

Filtres